Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative and innate immune cell inhibitory activity. All the work around duvelisib showed that this agent is a potent inhibitor of bo...
Duvelisib is indicated for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in adult patients who have trialed at least two prior therapies.
Pratia Onkologia Katowice, Katowice, Poland
Ospedale di Circolo, PO Varese, AO Ospedale di Circolo e Fondazione Macchi, Varese, Italy
Universitaetsklinikum Bonn AöR, Bonn, Germany
City of Hope Medical Center, Duarte, California, United States
OHSU Knight Cancer Institute, Portland, Oregon, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Northern Light Eastern Maine Medical Center, Brewer, Maine, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
Boston Medical Center, Boston, Massachusetts, United States
University of California - Los Angeles, Los Angeles, California, United States
Northwestern University - Feinberg School of Medicine, Chicago, Illinois, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
St. Vincent Frontier Cancer Center, Billings, Montana, United States
Ingalls Memorial Hospital, Harvey, Illinois, United States
Genesis Cancer Center, Hot Springs, Arkansas, United States
Stanford University Medical Center, Stanford, California, United States
University of Washington School of Medicine in St. Louis, Saint Louis, Missouri, United States
Washington University School of Medicine, Saint Louis, Missouri, United States
UT MD Anderson Cancer Center, Houston, Texas, United States
Azienda Ospedaliera Santa Maria di Terni/SC Oncoematologia, Terni, Umbria, Italy
Site Reference ID/Investigator# 148562, Harvey, Illinois, United States
Site Reference ID/Investigator# 147922, Chicago, Illinois, United States
Site Reference ID/Investigator# 145674, Baltimore, Maryland, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.